Real-World Use of Hypomethylating Agents (HMA)/Venetoclax Combinations in Patients with Myelodysplastic Neoplasms (MDS) in the Arabian Gulf Region

被引：0
|
作者：
Khadadah, Fatima [1 ]
Cherif, Honar [2 ]
El Omri, Halima [3 ]
Absi, Ahmed [4 ]
Merwass, Noor [5 ]
Abu Haleeqa, Mohamed I. [6 ]
Jaber, Waed [6 ]
Alhuraiji, Ahmad [7 ]
Pandita, Ramesh [1 ]
机构：
[1] Kuwait Canc control Ctr, Kuwait, Kuwait
[2] Natl Ctr Canc Care & Res, Hematol BMT, Doha, Qatar
[3] Hamad Univ, Ar Rayyan, Qatar
[4] Natl Guard Hlth Affairs, Princess Noorah Oncol Ctr, King Abdulaziz Med City Western Reg, Jeddah, Saudi Arabia
[5] Minist Natl Guard Hlth Affairs, Dept Adult Hematol & Stem Cell Transplantat, Princess Noorah Oncol Ctr, Jeddah, Saudi Arabia
[6] Sheikh Shakhbout Med Ctr, Abu Dhabi, U Arab Emirates
[7] Kuwait Canc Ctr, Shuwaikh, Kuwait
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181520
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Intensive chemotherapy (IC) versus hypomethylating agents (HMA) for the treatment of younger patients with myelodysplastic syndrome (MDS) and elevated bone marrow blasts.
    Strati, Paolo
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Borthakur, Gautam
    Konopleva, Marina
    Daver, Naval Guastad
    Dinardo, Courtney Denton
    Short, Nicholas James
    Yilmaz, Musa
    Naqvi, Kiran
    Pierce, Sherry
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Real-World Treatment Patterns Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents
    Zeidan, Amer M.
    Costantino, Halley
    Modi, Kushal
    Salimi, Tehseen
    Washington, Terri
    Epstein, Robert S.
    BLOOD, 2023, 142
  • [23] Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database
    Kewan, Tariq
    Bewersdorf, Jan Philipp
    Blaha, Ondrej
    Stahl, Maximilian
    Al Ali, Najla H.
    DeZern, Amy E.
    Sekeres, Mikkael A.
    Carraway, Hetty E.
    Desai, Pinkal
    Griffiths, Elizabeth A.
    Stein, Eytan M.
    Brunner, Andrew M.
    Amaya, Maria L.
    Zeidner, Joshua F.
    Savona, Michael R.
    Stempel, Jessica M.
    Chandhok, Namrata Sonia
    Cochran, Hunter
    Ramaswamy, Rahul
    Singh, Abhay
    Roboz, Gail J.
    Rolles, Benjamin
    Wang, Eunice S.
    Harris, Amyah C.
    Shallis, Rory M.
    Xie, Zhuoer
    Padron, Eric
    Maciejewski, Jaroslaw P.
    Della Porta, Matteo Giovanni
    Komrokji, Rami S.
    Sallman, David A.
    Zeidan, Amer M.
    BLOOD, 2023, 142
  • [24] Allogeneic Hematopoeitic Stem Cell Transplantation (AHSCT) Versus Hypomethylating Agents (HMA) in Patients (pts) with Myelodysplastic Syndrome (MDS): A Case-Control Study
    Tanaka, Maria F.
    Jabbour, Elias
    Kantarjian, Hagop M.
    Pierce, Sherry
    Champlin, Richard
    De Lima, Marcos
    Garcia-Manero, Guillermo
    BLOOD, 2011, 118 (21) : 743 - 744
  • [25] Real-world experience with hypomethylating agents and venetoclax as induction or salvage therapy followed by allogeneic stem cell transplantation in patients with acute myeloid leukemia
    Rautenberg, C.
    Stelljes, M.
    Acker, F.
    Holtick, U.
    Jost, E.
    Ragette, A.
    Kaivers, J.
    Tischer, J.
    Fraccaroli, A.
    Neuendor, N.
    Hanoun, M.
    Schmalbrock, L. K.
    Braitsch, K.
    Verbeek, M.
    Goetze, K.
    Bug, G.
    Reinhardt, C.
    Kroeger, N.
    Schroeder, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 193 - 193
  • [26] Venetoclax and Hypomethylating Agent in Previously Untreated Higher-Risk Myelodysplastic Syndromes and Genotype Signatures for Response and Prognosis: A Real-World Study
    Wang, Jing
    Fang, Zhijian
    Yang, Siyi
    Yan, Kexin
    Zhang, Jingjing
    Yu, Yanfang
    Ren, Yaoliang
    Jiang, Hao
    Jia, Jinsong
    Chen, Jianlin
    Li, Botao
    Chang, Yingjun
    Zhao, Xiaosu
    Huang, Xiaojun
    AMERICAN JOURNAL OF HEMATOLOGY, 2024,
  • [27] Selinexor in Combination with Azacitidine ( AZA) in Patients with Myelodysplastic Syndrome (MDS): A Real-World Retrospective Study
    Zhou, Huifen
    Wu, Xiaoxia
    Yang, Zhen
    Zhang, Xinhui
    Lu, Shenqi
    Wu, Depei
    Miao, Miao
    BLOOD, 2023, 142
  • [28] A Sequential Two-Stage Dose Escalation Study Evaluating The Safety and Efficacy Of Eltrombopag In Thrombocytopenic Patients With Myelodysplastic Syndrome (MDS) Resistant To Hypomethylating Agents (HMA)
    Komrokji, Rami S.
    Duong, Vu H.
    Zhang, Ling
    Lee, Ji-Hyun
    Padron, Eric
    Lancet, Jeffrey E.
    List, Alan
    BLOOD, 2013, 122 (21)
  • [29] Treatment Patterns and Characteristics Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents in a Real-World Setting
    Zeidan, Amer M.
    Divino, Victoria
    DeKoven, Mitch
    Wang, Elizabeth
    Chen, Justin
    Salimi, Tehseen
    Epstein, Robert S.
    BLOOD, 2022, 140 : 4047 - 4049
  • [30] DEMOGRAPHIC AND CLINICAL CHARACTERISTICS AMONG PATIENTS WITH MYELODYSPLASTIC SYNDROMES RECEIVING ORAL DECITABINE AND CEDAZURIDINE OR INTRAVENOUS/SUBCUTANEOUS HYPOMETHYLATING AGENTS IN A REAL-WORLD SETTING
    Zeidan, A.
    Martin, A.
    Costantino, H.
    Modi, K.
    Salimi, T.
    Washington, T.
    Epstein, R.
    LEUKEMIA RESEARCH, 2023, 128
12345